asid
impact
health
influenza
pose
seriou
threat
world
economi
season
flu
outbreak
commonplac
particular
pandem
kill
million
peopl
new
influenza
pandem
caus
novel
result
million
infect
countri
viru
also
classifi
highli
pathogen
avian
influenza
viru
caus
sever
ill
high
mortal
recent
studi
identifi
five
mutat
known
hemagglutinin
ha
protein
allow
viru
spread
air
ferret
furthermor
new
strain
influenza
virus
recent
detect
includ
genet
variat
influenza
viru
key
problem
result
genet
drift
genet
shift
make
almost
imposs
produc
time
suffici
effect
vaccin
prevent
epidem
outbreak
reason
antivir
drug
offer
import
option
combat
avian
flu
includ
highli
pathogen
avian
influenza
viru
current
two
class
drug
avail
target
ion
channel
neuraminidas
na
express
viru
envelop
respect
sinc
ion
channel
inhibitor
extrem
limit
clinic
applic
result
neurolog
side
effect
widespread
drug
resist
na
inhibitor
nai
current
effect
therapi
strain
influenza
b
virus
oseltamivir
zanamivir
licens
recommend
treatment
prevent
acut
uncompl
flu
caus
influenza
two
nai
peramivir
laninamivir
approv
season
use
japan
clinic
evalu
countri
peramivir
also
approv
use
korea
china
well
usa
accord
surveil
data
virus
test
surveil
suscept
oseltamivir
zanamivir
respect
http
wwwcdcgovfluprofessionalsantiviralsantiviraldrugresistancehtm
drug
offer
new
prospect
influenza
manag
howev
viru
strain
resist
nai
constantli
emerg
addit
dual
resist
oseltamivir
amantadin
detect
thu
urgent
import
investig
new
antivir
drug
influenza
viru
three
type
influenza
virus
b
c
influenza
belong
famili
orthomyxovirida
envelop
viru
genom
made
neg
sens
segment
rna
influenza
virus
classifi
subtyp
base
two
main
surfac
glycoprotein
ha
na
influenza
viru
life
cycl
divid
four
stage
figur
first
ha
bind
host
cell
sialic
acid
residu
second
endocytosi
occur
viru
enter
host
cell
endosom
endosom
low
ph
around
trigger
fusion
viral
endosom
membran
follow
releas
cytoplasm
vrnp
enter
nuclei
infect
cell
third
complet
transcript
replic
viral
genom
vrnp
export
nucleu
follow
assembl
bud
host
cell
membran
fourth
viral
particl
releas
cell
one
import
step
must
occur
newli
made
viral
particl
leav
plasma
membran
cleavag
sialic
acid
residu
glycoprotein
glycolipid
without
process
viral
particl
could
releas
plasma
membran
go
infect
neighbor
cell
recent
function
na
report
recent
propos
na
may
facilit
viru
entri
target
cell
initi
stage
viral
infect
attempt
made
analyz
new
role
well
known
na
promot
viru
access
target
cell
airway
mucou
degrad
consist
hypothesi
studi
show
na
facilit
spread
viru
mucou
cover
human
airway
epithelium
like
mechan
relat
remov
decoy
receptor
mucin
cilia
cellular
glycocalyx
howev
lung
cancer
mdck
cell
wide
use
influenza
model
secret
mucin
therefor
possibl
na
adopt
novel
way
aid
viru
entri
recent
studi
demonstr
na
inde
play
direct
earli
role
influenza
viru
entri
ohuchi
et
al
exampl
found
na
facilit
viru
transfer
site
site
thu
facilit
viru
entri
target
cell
note
activ
block
nai
author
suggest
na
express
directli
impact
influenza
viru
fusion
viru
infect
effici
base
enzymat
activ
na
unchang
ha
na
replac
background
viru
signific
effect
effici
infect
initi
viru
releas
fusion
infect
cell
result
call
research
confirm
role
na
facilit
influenza
viru
entri
suscept
cell
surprisingli
sever
research
group
report
na
acquir
capac
bind
receptor
report
challeng
gener
accept
concept
na
effector
viral
fusion
releas
figur
new
concept
na
bind
receptor
host
cell
surfac
complement
process
ha
receptor
bind
recent
report
reveal
na
mutant
promot
hemagglutin
caus
attach
recent
isol
human
virus
via
na
sialic
acid
receptor
refractori
catalyt
cleavag
although
ha
still
requir
viral
entri
specif
na
appear
complement
defici
ha
bind
thu
na
display
two
biolog
activ
includ
complementari
bind
specif
ha
cleavag
sialic
acid
earli
late
stage
respect
viral
life
cycl
subsequ
shown
na
mutant
sialic
acid
bind
activ
avian
human
sialic
acid
glycan
activ
site
oseltamivir
block
bind
sialic
acid
human
isol
highlight
na
mutant
play
role
viral
entri
anoth
mutant
enabl
na
subtyp
complet
function
new
mutat
enabl
recent
human
isol
grow
high
titer
even
absenc
ha
function
specif
na
allow
na
mediat
viral
infect
rbc
agglutin
manner
revers
block
nai
antibodi
subsequ
studi
shown
na
human
influenza
virus
isol
earli
gain
function
howev
research
still
challeng
theori
na
facilit
viru
entri
therefor
properti
na
must
involv
still
unknown
mechan
therefor
call
accumul
relev
vitro
vivo
data
inde
mani
factor
must
taken
consider
specul
possibl
mechan
na
includ
influenza
subtyp
speci
cell
line
also
bind
site
stalk
length
variat
function
domain
substrat
specif
na
potenti
glycosyl
site
might
also
affect
na
activ
date
four
licens
nai
avail
treatment
prophylaxi
influenza
viru
infect
figur
nai
class
antivir
drug
recommend
treatment
prophylaxi
influenza
b
infect
includ
current
emerg
avian
strain
unfortun
develop
spread
exist
strain
significantli
limit
effect
inhibitor
na
remain
promis
target
drug
discoveri
nai
resist
give
ad
urgenc
search
novel
nai
blockad
viral
entri
would
certainli
promis
therapeut
strategi
fight
viru
infect
includ
influenza
viru
notabl
applic
viral
entryfus
inhibitor
peptid
enfuvirtid
either
alon
combin
antiviru
agent
becom
attract
antivir
strategi
moreov
small
molecul
potenti
entri
inhibitor
object
research
mani
year
date
howev
drug
abl
block
viral
entri
avail
treatment
prevent
influenza
hand
base
specul
characterist
na
studi
thu
far
show
na
play
role
earli
stage
viru
life
cycl
ask
whether
nai
could
develop
entri
inhibitor
influenza
infect
na
contain
homotetramer
glycoprotein
stalk
domain
anchor
viral
membran
globular
head
contain
catalyt
site
activ
site
na
compos
function
residu
surround
framework
residu
number
system
residu
highli
conserv
na
subtyp
base
conserv
catalyt
site
intens
research
focus
structur
modif
exist
nai
well
design
novel
nai
previous
review
exampl
new
deriv
oseltamivir
prepar
modifi
amino
group
glycyl
acetyl
benzyl
prolyl
moieti
order
develop
novel
influenza
viru
inhibitor
locat
residu
loop
edg
activ
site
na
sensit
bind
oseltamivir
suggest
critic
residu
involv
catalyt
activ
na
princip
role
believ
stabil
transit
state
intermedi
cleavag
reaction
key
hydrogen
bond
glycosid
oxygen
sialic
acid
residu
critic
interact
enzymat
activ
na
figur
residu
wild
type
na
may
function
scissor
cleav
sialic
acid
receptor
therefor
understand
na
exhibit
detect
bind
sialosid
howev
aspart
acid
na
replac
glycin
na
abl
bind
receptor
result
attach
viru
via
na
sialic
acid
receptor
red
blood
cell
entri
viru
carri
na
mutat
could
block
nai
indic
locat
bind
site
na
receptor
shown
figur
pivot
hydrogen
bond
residu
involv
cleavag
activ
na
elimin
insuffici
length
residu
side
chain
therefor
unlik
na
bind
na
mutat
sialic
acid
receptor
effect
cleav
receptor
rather
mediat
entri
viru
target
cell
characterist
na
describ
preced
text
alter
specif
na
mainli
amino
acid
substitut
residu
na
worth
note
na
mutat
readili
bind
sialic
acid
receptor
also
sensit
nai
activ
would
repres
nonclass
role
na
na
variant
turn
common
perhap
could
provid
valuabl
insight
na
potenti
emerg
target
develop
influenza
viru
entri
inhibitor
provid
data
expand
avenu
research
small
molecul
abl
block
na
activ
lead
turn
new
class
nai
target
viral
entri
novel
nai
becom
identifi
influenza
viru
entri
may
prove
effect
use
combin
antivir
agent
combin
drug
differ
mode
action
strategi
success
antivir
therapi
one
may
particularli
use
addit
antivir
effect
well
avoid
select
resist
virus
instanc
combin
oseltamivir
antivir
agent
investig
make
possibl
optim
suppress
influenza
infect
similarli
novel
nai
could
design
synthes
combinatori
use
becom
best
option
prophylaxi
control
pandem
condit
much
remain
learn
influenza
viral
life
cycl
includ
molecular
mechan
underli
viral
entri
howev
new
role
na
potenti
target
earli
stage
viral
entri
led
renew
interest
nai
highlight
develop
new
nai
viru
entri
particular
emphasi
use
combin
therapi
therefor
necessari
continu
studi
role
na
viru
life
cycl
anticip
identifi
novel
target
develop
new
antivir
agent
treatment
prevent
influenza
viru
infect
author
compet
interest
